Sulbactam has been combined with the third-generation Recently, the availability of newer, relatively nontoxic blactam drugs with broader and more potent antibacterial activity cephalosporin cefoperazone. The addition of sulbactam to cefoperazone extends cefoperazone's activity against b-lactahas led to the introduction of the concept of monotherapy for febrile granulocytopenic patients. Potential advantages of mase-producing aerobic bacteria and anaerobes and increases its activity against cefoperazone-susceptible organisms [10, monotherapy are less toxicity and decreased costs. Several controlled, randomized trials have found that single-agent therapy 11]. Sulbactam/cefoperazone has been shown to be effective therapy in granulocytopenic mice infected with b-lactamasewith either ceftazidime or imipenem is as effective as combination therapy for empirical treatment of febrile granulocytopenic producing Pseudomonas aeruginosa and Escherichia coli organisms [12] . patients [1 -6] . Consequently, at some oncology centers, ceftazidime or imipenem alone is now used routinely for suspected
In open noncomparative clinical trials, sulbactam/cefoperazone was also effective as treatment for bacteremia and pneubacterial infection in the granulocytopenic patient.
One of the concerns about monotherapy with a single bmonia in febrile oncology patients [13, 14] . Therefore, we performed a prospective, randomized study comparing the eflactam drug is that extensive use of this type of therapy will contribute to the emergence and spread of b-lactam-resistant, ficacy and safety of sulbactam/cefoperazone with imipenem as monotherapy for febrile granulocytopenic patients. Imipenem gram-negative organisms [4, 7 -9] . A common mechanism of resistance to b-lactam drugs among bacteria is the production was chosen as the comparative agent since administration of imipenem alone is the most common empirical therapy for of b-lactamase enzymes that destroy the antibiotics. To counter resistance to b-lactam drugs, b-lactam antibiotics are now befebrile granulocytopenic patients at the UCLA Center for the Health Sciences and since it has also been found, in some trials ing combined with a b-lactamase inhibitor that limits the destructive action of b-lactamases. Sulbactam is one of several [5, 8] , to be more effective than ceftazidime alone in febrile granulocytopenic patients. currently available inhibitors that block a variety of b-lactamases produced by both gram-positive and gram-negative bacteria [10] .
Patients and Methods
Patients. Patients hospitalized at the UCLA Center for the Patients with severe hepatic disease -defined as an increase (infection suspected but no site or organism identified). The subsequent response to therapy was classified as one of the (to greater than six times the upper limit of normal) in the level of total serum bilirubin, serum aspartate aminotransferase, or following: (1) improvement (disappearance of fever, overall clinical improvement, and eradication of the infecting organism serum alanine aminotransferase -and patients with a history of seizures were excluded. Informed consent was obtained from without modification of antibiotic therapy); (2) failure (persistence of fever or of the infecting organism, requiring modificaeligible patients or their relatives in a manner approved by the UCLA Human Subject Protection Committee. Patients were tion of antibiotic therapy); or (3) nonevaluable (infection considered unlikely, nonbacterial infection, or protocol violation). then randomly assigned to receive either sulbactam/cefoperazone or imipenem for empirical therapy.
Superinfection was defined as a new microbiologically documented infection that appeared either during therapy or within Antibiotic regimens. Sulbactam/cefoperazone (Sulperazon; Pfizer, Groton, CT) in a 1:2 ratio was given intravenously at 3 days of the discontinuation of antibiotic therapy. Statistical analysis. A two-tailed Fisher's exact test was a dosage of 2 g of sulbactam and 4 g of cefoperazone every 12 hours. The imipenem (Primaxin; Merck and Co., West Point, used to compare differences in proportions between groups. Differences between medians were analyzed by the Mann-PA) dosage was 500 mg intravenously every 6 hours. The dosages of sulbactam and imipenem were adjusted for patients Whitney U test. Confidence intervals (CIs) of 95% for differences between the two study groups were determined where with impaired renal function [15, 16] . Each antimicrobial agent was infused intravenously over 30 -60 minutes. All patients in appropriate. For sample size calculations, it was estimated that the overall response rate with imipenem would be at least 70%. both treatment groups received 10 mg of vitamin K on the day of randomization and then once per week during therapy.
It was hypothesized that the use of sulbactam/cefoperazone might increase the response rate to 80%. For a study to detect Laboratory studies. Before the initiation of therapy, cultures of blood and of specimens from other suspected sites such an increase at the one-sided level of significance of .05 with 80% power, 119 patients in each treatment group would of infection were performed. Patients with bacteremia or a documented site of infection associated with a positive culture be required [18] . had cultures repeated during and after therapy, unless the site of infection was not accessible to repeated sampling. All organResults isms isolated from clinical specimens were identified by standard criteria in the clinical microbiology laboratory of the Patients' characteristics. A total of 209 patients were enrolled in the trial. Six patients were excluded from analysis, UCLA Center for the Health Sciences [17] . Antimicrobial susceptibility testing of bacterial isolates was performed by the for the following reasons: the patient was not granulocytopenic (3 cases), infection was considered unlikely (1 case), an immebroth microdilution method [17] . Susceptibility breakpoints (MICs) were as follows: sulbactam/cefoperazone, 8 mg per diate hypersensitivity reaction developed after a single dosing of study drug (1 case), or the patient was withdrawn from the mL/£16 mg per mL; cefoperazone alone, £16 mg/mL; and imipenem, £4 mg/mL. study (1 case). The remaining 203 patients were evaluated for both efficacy and toxicity. There were 101 patients in the Patients were examined daily during therapy for clinical symptoms and signs of side effects related to the study antibiotsulbactam/cefoperazone group and 102 patients in the imipenem group. Patients in the two treatment groups were similar ics. Complete blood cell counts, prothrombin times, and electrolyte and serum creatinine levels were determined and uriwith regard to sex, underlying disease, degree and duration of granulocytopenia, previous prophylaxis with oral quinolones, nalyses and liver function studies were performed before, during, and after therapy to assess possible treatment-related and use of hematopoietic growth factors (table 1). The median age of patients in the sulbactam/cefoperazone side effects. Antibiotic-related nephrotoxicity was defined as an increase in the serum creatinine level of ú0.4 mg/dL after group was 47 years, compared with 39 years in the imipenem group. This age difference was not significant (P Å .83). Apother causes of nephrotoxicity (hypotension, amphotericin B, or other nephrotoxic drugs) had been excluded. Possible antibiproximately one-half of the patients were undergoing bone marrow or peripheral stem cell transplantation. Most patients otic-related coagulotherapy was defined as an increase in the prothrombin time of §2 seconds above the control value, temin both groups had initial granulocyte counts of õ100/mm 3 . Persistent granulocytopenia (õ500 granulocytes/mm 3 throughporally related to the administration of the study drugs and not explainable by other obvious causes of coagulopathy. Patients out the course of therapy with the study antibiotic) was associated with Ç25% of the treatment courses. The median duration were also observed closely for seizures and episodes of hemorrhage requiring immediate RBC or platelet transfusions.
of therapy was 12 days in the sulbactam/cefoperazone group and 14 days in the imipenem group. Evaluation of response. Initial febrile episodes were classified into one of the following groups: (1) microbiologically Clinical response to therapy. Table 2 summarizes the clinical response to therapy. The overall clinical response rate in the documented infection (both site of infection and organism identified); (2) clinically documented infection (site of infection sulbactam/cefoperazone group was 88% and not significantly different than the overall response rate of 81% in the imipenem identified but no organism isolated); or (3) 13% -58%; P Å .06). Of the six gram-negative infections failLymphoma 4 (4) 9 (9) ing to respond to imipenem, only one was caused by an organMultiple myeloma 2 (2) 2 (2) ism (P. aeruginosa) resistant to imipenem. The response rate
Hairy cell leukemia 1 (1) 1 (1) of gram-positive infections was similar in the sulbactam/cefopAplastic anemia 2 (2) 1 (1) Solid tumor 5 (5) 5 (5) erazone group (83%) and the imipenem group (86%).
Bone marrow or stem cell transplant 51 (50) 55 (54) The most common gram-positive pathogen was viridans and then vancomycin. The other patient who died had poly-õ100/mm Response related to granulocyte count. The response to therapy of patients with microbiologically or clinically documented infection was evaluated in relation to the initial granulocyte count (at the start of therapy) and any subsequent change group (CI, 02% to 17%; P Å .17). The response rates for microbiologically documented infections, clinically docuduring therapy. There were 40 patients in the group receiving sulbactam/cefoperazone and 40 patients in the group receiving mented infections, and possible infections in the two groups were also similar.
imipenem with microbiologically or clinically documented infections. Among patients with an initial granulocyte count of Bacteriologic response to therapy. Table 3 compares the response to therapy by bacterial pathogen. The number of ú100/mm 3 , the response rates were 6 of 8 (75%) and 3 of 5 (60%) for sulbactam/cefoperazone and imipenem, respectively gram-positive organisms (52 isolates) obtained from pretherapy cultures was twice the number of gram-negative organisms (26 (CI, 037% to 67%; P Å 1.0). Among patients whose initial granulocyte count of isolates). Of the 166 patients receiving prophylactic norfloxacin before the study, 42 (25%) had gram-positive infections caused õ100/mm 3 subsequently rose to ú100/mm 3 during therapy, the response rates were 26 of 28 (93%) and 28 of 29 (97%) by a total of 46 strains of gram-positive bacteria. In contrast, only 2 of 37 patients (5.4%) not receiving prophylactic norfor sulbactam/cefoperazone and imipenem, respectively. When the granulocyte count remained below 100/mm 3 throughout the floxacin developed gram-positive infections, caused by a total of two gram-positive bacteria (CI, 10% -30%; P Å .007).
course of therapy, the response rates were 2 of 4 (50%) and 3
/ 9c48$$mr23 02-05-98 21:33:38 cida UC: CID have been additional risk factors for seizures in two of the imipenem recipients who had seizures.
soft-tissue infection was the only pretherapy gram-positive isoDiscussion late resistant to both study drugs and cefoperazone.
Only eight of the 26 pretherapy gram-negative isolates were In this prospective, randomized, comparative study, both sulbactam/cefoperazone and imipenem were effective as empirsusceptible to narrow-spectrum antibiotics (ampicillin and cefazolin). In contrast, all 52 pretherapy gram-positive isolates were ical monotherapy for febrile, granulocytopenic patients. There was no substantial difference in the overall clinical responses susceptible to one or more narrow-spectrum antibiotics used to treat gram-positive infections (vancomycin, oxacillin, penito treatment with sulbactam/cefoperazone (88%) or imipenem (81%) (table 2). These response rates compare quite favorably cillin, ampicillin, or cefazolin).
Superinfections. The incidence of superinfections was 16% with the results of our own previous UCLA trials of empirical antibiotic therapy for febrile granulocytopenic patients as well among both sulbactam/cefoperazone and imipenem recipients (table 4). Superinfections occurred in 10% of patients (8 of as studies reported by other investigators [4, 19 -25] . Indeed, the overall clinical and microbiological response rates of ú80% 80) with an initial documented infection and in 19% of patients (24 of 123) with initial fever but no documented infection. The observed in this study are notably higher than those recently published in reports of other single-center and multicenter trials types of organisms causing superinfection were similar for each study drug. P. aeruginosa and Stenotrophomonas maltophilia evaluating monotherapy for granulocytopenic patients (clinical response rates of 52% -72%) [2 -6, 8, 26] . were the most common gram-negative bacillary organisms causing superinfection. Two of the four P. aeruginosa and Several factors likely contributed to the high rates of response to either sulbactam/cefoperazone or imipenem in this S. maltophilia isolates causing superinfection in patients receiving sulbactam/cefoperazone were resistant to sulbactam/cefopstudy. First, empirical vancomycin therapy in cases of persistent fever without isolation of a resistant organism is not used erazone. On the other hand, all six isolates of P. aeruginosa or S. maltophilia causing superinfection in patients receiving at UCLA. Empirical glycopeptide therapy has been a frequent modification in other studies and thus a common cause for imipenem were resistant to imipenem.
Four of the five gram-positive organisms causing superinfecfailure of study antibiotics [26, 27] . Second, in contrast to our previous six UCLA antibiotic trials in which 40% -50% of tion in the sulbactam/cefoperazone group were resistant to sulbactam/cefoperazone, while all five gram-positive organisms patients had persistent granulocytopenia throughout the course of their antibiotic therapy [4, 20 -24] , only 25% of patients in causing infection in the imipenem group were resistant to imi-/ 9c48$$mr23 02-05-98 21:33:38 cida UC: CID this study had persistent granulocytopenia (table 1) . This frestudies have shown the efficacy of oral quinolone prophylaxis in reducing the morbidity and mortality associated with aerobic quent and favorable recovery from granulocytopenia was likely related to the extensive use of hematopoietic growth factors gram-negative bacillary infections in granulocytopenic patients, at the risk of increasing bacteremias due to viridans and/or peripheral stem cell infusions, which were not used in our previous antibiotic trials [28 -30] . Finally, in keeping with group streptococcus [34, 35] . In most cases, these viridans group streptococcal infections can be treated successfully with the trend at other oncology centers, in this study there were very few P. aeruginosa or b-lactam-resistant gram-negative b-lactam agents or the subsequent addition of vancomycin. However, as demonstrated by two patients in this study, ARDS infections, which may limit the efficacy of single-agent blactam therapy [4, 7 -9] .
is an occasional complication of this infection and can be fatal. Pretherapy gram-positive isolates in this study were all susOnly a few controlled trials evaluating the efficacy of sulbactam/cefoperazone in a large number of febrile granulocytopenic ceptible to vancomycin and, in some cases, to oxacillin, penicillin, ampicillin, or cefazolin. Nevertheless, it has been our expepatients have been reported. El Haddad compared sulbactam/ cefoperazone with piperacillin plus amikacin in 45 febrile, grarience that attempts to narrow the spectrum of antimicrobial therapy for a granulocytopenic patient with only a documented nulocytopenic pediatric patients [31] . The response rates were 77% (23 of 30 patients) among sulbactam/cefoperazone recipigram-positive infection are frequently associated with subsequent clinical deterioration. Indeed, rapidly fatal breakthrough ents and 44% (7 of 16 patients) among recipients of piperacillin plus amikacin. Bodey and colleagues reported no significant bacteremia caused by gram-negative bacilli has been reported in such situations [36] . difference in the overall rates of response to sulbactam/cefoperazone plus vancomycin (144 of 194 patients, or 74%) and Both sulbactam/cefoperazone and imipenem were generally well tolerated. Among b-lactam drugs, cefoperazone is imipenem plus vancomycin (128 of 175 patients, or 73%) among febrile granulocytopenic patients at M.D. Anderson relatively unusual for its excretion primarily by hepatobiliary mechanisms [37] . This may account for the greater incidence Hospital (Houston) [32] . However, nausea, vomiting, and Clostridium difficile colitis occurred more often in patients receiving of diarrhea among patients receiving sulbactam/cefoperazone in this trial. Cefoperazone also has a methylthiotetraimipenem plus vancomycin. In another randomized trial comparing sulbactam/cefoperazone to imipenem as monotherapy zole side chain, which may inhibit vitamin K 2,3-epoxide reductase and cause hypoprothombinemia [38] . However, all for febrile granulocytopenic patients, Bickers et al. found similar but low rates of response to sulbactam/cefoperazone (26 of patients in this study received weekly prophylactic vitamin K, and there was no appreciable increased risk for coagulo-58 patients, or 44%) and imipenem (19 of 58 patients, or 33%) because of the frequent addition of empirical amikacin therapy pathy or hemorrhage in patients treated with sulbactam/cefoperazone. to both study-antibiotic regimens [33] .
The number of gram-positive organisms isolated in preThree recipients of imipenem were the only patients in this study who experienced seizures. Studies of laboratory animals therapy cultures in this study was twice the number of gramnegative organisms (table 3) . The most common gram-positive have shown the potential of imipenem to cause seizures [39] . CNS disease and inappropriately high doses in patients with pathogen was viridans group streptococcus, which caused 21 bacteremias. A likely factor contributing to this predominance impaired renal function are the principal risk factors for seizures associated with imipenem [40] . Two of the three imiof gram-positive pathogens and especially of viridans group streptococcus was the use of pretherapy norfloxacin prophypenem recipients who had seizures had these risk factors, and there was a delay in reducing their imipenem dose. laxis by Ç80% of the patients enrolled in the study [34] 
